The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
what a mess 3 rns out you could have put all the info on 1 but they have spooked the market with there 1st rns so crash goes the share price ( perhaps this was there plan) mmm dodgy
Chairman's Statement Since I last reported, Plant Impact plc ("Plant Impact, the "Company" and together with its subsidiaries, the "Group") has made good progress with all elements of its strategy. The intent of the Board which I described then, was to focus the Group towards sales in high value horticultural crops close to home, to secure a first move into broad acre crops in partnership with an agrochemical major in Brazilian soy and to secure distribution for our turf (golf) product in the USA. All of these have been accomplished. A new product for high-value tree fruit launched in the UK and Holland (Amētros) was well received by growers in its first year. We were delighted to secure a significant partnership programme with Bayer CropScience to launch Veritas in the vast Cerrados soy area in Brazil (which is described in a separate Q1 2014 trading update also released today), and we made our first trial sales into US golf in preparation for a launch in 2014. These are all exciting foundation achievements, exemplifying management's ability to deliver to strategy. Our balance sheet was strengthened in May 2013 by the repayment of an outstanding development loan to Arysta LifeScience Corporation ("Arysta") of £652,276. Plant Impact is now debt free. In the period, the Company raised equity capital of £2,368,588, primarily to fund its expansion into Brazil and the launch of new products into European markets. Less satisfactory were the European sales for the sixteen month transition period. In our May trading update, we highlighted our objective to achieve break-even operating income and cash flow in the six month trading period ended 31 July 2013. We did not achieve that. The business over that reporting period relied primarily on the Northern European sector, specifically our markets in the United Kingdom, Benelux, France and Germany. Each were challenged by high in-market stocks of our products which we expected distribution to sell out and then re-order. The very cold and prolonged spring coupled with a hot dry summer deterred growers from investing in new products and so farmer usage did not pull through enough distributor carry-over stock to trigger re-ordering. However, the decline in sales into the channel masked a small increase in farmer usage year-on-year. Furthermore, management made impressive progress broadening and deepening awareness of the performance of Plant Impact products at the grower level. This is an accumulating asset that we expect will be converted into sales in the coming seasons. I am delighted by the quality of staff now committed to Plant Impact and their achievements this year. Further, I should like to thank you, our shareholders, for the support you have given Plant Impact in the last year and for your interest in the Company. It was a pleasure to have a 'full house' at our mid-summer investors' day in Rothamsted. It was ou
o Change of Financial Year from 31 March to 31 July; sixteen month transition period completed o Decrease in turnover to £1,601k due to decline in Europe (2012: £1,927k) o Crop nutrient revenue £1,351k (2012: £1,927k) o Pest control revenue £250k (2012: nil) o Crop nutrient gross profit margins reduced to 67% due to product mix (2012: 75%) o Exceptional Expense of nil (2012: £475k) o Operating Loss reduced £1,803k (2012: £1,929k) o Cash at 31 July 2013 of £1,266k (2012: £1,346k) o Borrowings at 31 July 2013 of nil (2012: £842k) Post Year End o First invoiced sales of Veritas to Brazil o Shipments of first product to US turf market
why 2 rns in same day? one with all the facts would do what a mess perhaps the bod need performance related pay to get them in action
CHAIRMAN'S STATEMENT FOR THE YEAR ENDED 31st DECEMBER 2012 The last 12 months have delivered important positive developments both as to clinical advancements on a number of the Group's proprietary pipeline products as well as in respect of our planned transition to the United States. Let me first address major developments in respect of some of our proprietary drug candidates: Xenetic The Group will be commencing its first Western clinical trial in June/July 2013 by way of a Phase II FDA/ICH-compliant clinical trial in Australia for ErepoXen®, our PolyXen®-based biologic candidate for anaemia in pre-dialysis patients with Chronic Kidney Disease ("CKD"). The trial has been contracted with and is being conducted by Novotech (Australia) Pty Limited, an Australian-based Clinical Research Organisation ("CRO"), and is expected to finally report completion of Phase II studies in H1-2015. SynBio LLC Phase III trials for ErepoXen® commenced in Russia in May 2013 which, subject to good clinical outcomes, would lead to market approval of the drug for Russia and the Former CIS by end-2014 with the commencement of sales in 2015. This would also permit the Group to enter non-Russian/CIS markets (such as Brazil and other territories that recognise Russian approvals) and thereby expand the royalty income channels for the Group. Conducting ongoing clinical trials on our OncoHist™ candidate for both Acute Myeloid Leukaemia and for Non-Hodgkin's Lymphoma, with, to date, no Serious Adverse Events ("SAE") reported in either trial. Pharmsynthez Commenced clinical trials for our ImuXen®-based Multiple Sclerosis candidate, MyeloXen™ in November 2012 and has completed Phase I in healthy volunteers with no SAE. The trial has now entered the Phase II stage in patients. The dose-ranging phase is expected to be completed by Q3-2013 and dose confirmation studies in patients are expected to commence before the end of 2013. Completed pre-clinical work on PulmoXen™, our PolyXen®-based biologic proprietary candidate for Cystic Fibrosis and now is expected to move the candidate into the clinic in Q3-2013. Serum Institute CHAIRMAN'S STATEMENT FOR THE YEAR ENDED 31st DECEMBER 2012 The last 12 months have delivered important positive developments both as to clinical advancements on a number of the Group's proprietary pipeline products as well as in respect of our planned transition to the United States. Let me first address major developments in respect of some of our proprietary drug candidates: Xenetic The Group will be commencing its first Western clinical trial in June/July 2013 by way of a Phase II FDA/ICH-compliant clinical trial in Australia for ErepoXen®, our PolyXen®-based biologic candidate for anaemia in pre-dialysis patients with Chronic Kidney Disease ("C
2 May 2013 Brady plc ("Brady" or the "Company") Director Share Dealing The Company has been informed that on 1 May 2013 Pat Brazel acquired a beneficial interest in 50,000 ordinary shares in the Company at 72p each by means of a spread bet. Following this transaction Mr. Brazel has an interest in 281,682 shares representing 0.29 per cent. of the Company's issued share capital.